Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Indivior PLC (NASDAQ: INDV) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a pharmaceutical issuer focused on opioid use disorder (OUD) treatments, Indivior uses its filings to report financial results, strategic initiatives, governance changes, and key legal and regulatory matters.
Investors can review Form 8-K current reports in which Indivior details material events such as quarterly financial results, updates on the Indivior Action Agenda, restructuring charges, optimization of its Rest of World business, and changes to executive compensation or board composition. Other 8-K items describe the company’s intent to redomicile from the U.K. to Delaware, shareholder approvals of a scheme of arrangement and amended articles of association, and the conclusion of a legacy U.S. Department of Justice resolution agreement.
Through its periodic reports (Forms 10-K and 10-Q, when available on EDGAR), readers can examine segment performance, revenue composition, R&D spending, and risk factors related to Indivior’s OUD-focused portfolio, including SUBLOCADE, SUBOXONE Film, PERSERIS, and OPVEE. These filings also typically include detailed discussions of non-GAAP measures such as adjusted EBITDA and non-GAAP operating expenses, along with reconciliations to U.S. GAAP metrics.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important points in lengthy filings, helping users quickly understand changes in guidance, restructuring actions, legal exposures, or capital structure. Real-time updates from EDGAR mean that new Indivior filings, including any future proxy statements on executive compensation and Form 4 insider transaction reports, are surfaced promptly.
By using this page, investors, analysts, and other stakeholders can efficiently navigate Indivior’s SEC reporting history, monitor developments in its OUD pharmaceutical business, and interpret the financial and governance implications of its regulatory disclosures.
Indivior Pharmaceuticals, Inc. director Juliet Thompson reported a grant of 3,722 restricted stock units of common stock on January 26, 2026 at a price of $0 per share. After this award, she beneficially owns 7,572 shares directly, with an additional 5,775 shares held indirectly by her spouse. The RSUs vest on the day immediately before the first annual stockholders’ meeting following the grant date, subject to her continued service.
Indivior Pharmaceuticals director Keith Humphreys received an equity grant of 3,722 shares of common stock on January 26, 2026, reported as an acquisition at a price of $0 per share. Following this grant, he beneficially owns 9,524 shares directly.
The award is structured as restricted stock units (RSUs), with each RSU representing a contingent right to one share of common stock. The RSUs vest on the day immediately preceding the first annual stockholders’ meeting after the grant date, conditioned on his continued service as of the vesting date.
Indivior Pharmaceuticals, Inc., a new Delaware corporation, has completed a U.S. domestication in which it became the ultimate parent of Indivior PLC and its subsidiaries through a court-approved scheme of arrangement. Each Indivior PLC ordinary share was cancelled and replaced on a one-for-one basis with Indivior Pharmaceuticals common stock, par value $0.001 per share. Indivior PLC ordinary shares ceased trading on Nasdaq, and Indivior Pharmaceuticals common stock now trades on the Nasdaq Global Select Market under the same symbol, INDV, with CUSIP 45579U109.
The company amended an existing note purchase agreement so financial reporting is now provided by Indivior Pharmaceuticals, and authorized indemnification agreements for its directors and executive officers to the fullest extent permitted under Delaware law. The same directors and executive officers continue in their roles, and existing equity plans were assumed and amended so awards will settle in Indivior Pharmaceuticals common stock.
Indivior Pharmaceuticals also adopted a new 2026 Omnibus Equity Incentive Plan reserving up to 17,500,000 shares, subject to recycling of forfeited awards, as well as a detailed non‑employee director compensation policy that combines cash retainers with annual and one‑time restricted stock unit awards.
BlackRock, Inc. has filed an amended Schedule 13G reporting beneficial ownership of 17,806,183 shares of INDIVIOR PLC common stock, representing 14.3% of the outstanding class as of the event date. BlackRock reports sole power to vote 17,585,684 shares and sole power to dispose of 17,806,183 shares, with no shared voting or dispositive power.
The filing is made on a passive basis under Schedule 13G, with BlackRock certifying that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Indivior. The filing notes that one investor, iShares Core S&P Small-Cap ETF, has an interest in more than five percent of Indivior’s outstanding common stock.
Indivior PLC filed a current report stating that on January 8, 2026 it issued a press release providing its financial guidance for 2026 and updated its corporate presentation. These materials are being made available to investors as supplemental information.
The 2026 financial guidance press release is included as Exhibit 99.1 and the updated corporate presentation is included as Exhibit 99.2 to the report, giving the market more detail on Indivior’s expected performance and strategic messaging for the year.
Indivior PLC director Ryan Barbara reported acquiring 775 Ordinary Shares on January 5, 2026 at a price of $35.3926 per share. These shares were received through participation in a Non-Executive Director Purchase Plan, under which a portion of director fees is taken in stock instead of cash. Following this transaction, Barbara beneficially owned 1,963 Ordinary Shares directly. This reflects a routine equity-based compensation election rather than an open-market investment decision.
Indivior PLC director Keith Humphreys reported acquiring additional ordinary shares in the company. On January 5, 2026, he obtained 775 ordinary shares at a price of $35.3926 per share, increasing his direct beneficial holdings to 5,802 shares.
The shares were acquired through Humphreys’ participation in a Non-Executive Director Purchase Plan, under which a portion of his fees for serving as a director is received in stock instead of cash. This filing reflects a compensation-related share purchase rather than an open-market discretionary trade.
Indivior PLC director Daniel A. Ninivaggi reported acquiring 775 ordinary shares of the company on January 5, 2026 at a price of $35.3926 per share.
The filing shows these shares were obtained through a Non-Executive Director Purchase Plan, where a portion of his director fees is taken in stock instead of cash. Following this transaction, he beneficially owned 16,923 ordinary shares, held directly.
Indivior plc director Mark Stejbach reported acquiring 775 ordinary shares of Indivior on January 5, 2026 at a price of $35.3926 per share. Following this transaction, he beneficially owns 16,847 ordinary shares, held directly.
According to the disclosure, the shares were received through a Non-Executive Director Purchase Plan, under which a portion of his director fees is taken in stock instead of cash. This reflects compensation taken in equity rather than an open-market investment decision.